ICON PLC
NASDAQ:ICLR
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
187.22
346.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
ICON PLC
ICON PLC
Cash Equivalents
ICON PLC
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ICON PLC
NASDAQ:ICLR
|
Cash Equivalents
$695.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
M
|
Malin Corporation PLC
ISEQ:MLC
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ICON PLC
Glance View
ICON PLC, a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries, has carved a niche for itself in the critical world of clinical research. Founded in 1990 and headquartered in Dublin, Ireland, ICON PLC combines innovative technologies with deep industry expertise to assist clients at every stage of their product development journey. As the demand for faster and more efficient drug development grows, ICON's comprehensive service offerings—including clinical trial management, analytics, and regulatory consulting—position the company as a vital partner for organizations aiming to bring new therapies to market. With a keen focus on improving patient outcomes and ensuring high-quality results, ICON has built a reputation for operational excellence and customer satisfaction. For investors, ICON PLC represents a compelling opportunity in the booming healthcare sector. Its robust financial performance, characterized by consistent revenue growth and healthy profit margins, reflects its capacity to adapt to the evolving landscape of clinical research. Moreover, the company’s strategic acquisitions and investments in cutting-edge technology underscore its commitment to remaining at the forefront of industry advancements. As ICON continues to expand its global footprint and leverage its extensive expertise, it stands to benefit from the rising demand for clinical services and the increasing complexity of modern drug development. With a strong management team and a clear vision for the future, ICON PLC is well-positioned to deliver sustainable value to its shareholders.
See Also
What is ICON PLC's Cash Equivalents?
Cash Equivalents
695.5m
USD
Based on the financial report for Sep 30, 2024, ICON PLC's Cash Equivalents amounts to 695.5m USD.
What is ICON PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
16%
Over the last year, the Cash Equivalents growth was 122%. The average annual Cash Equivalents growth rates for ICON PLC have been -12% over the past three years , 11% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
